Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
13.37
-0.35 (-2.55%)
At close: Mar 20, 2026, 4:00 PM EDT
13.63
+0.26 (1.94%)
After-hours: Mar 20, 2026, 7:40 PM EDT
Assertio Holdings Revenue
In the year 2025, Assertio Holdings had annual revenue of $118.71M, down -5.00%. Assertio Holdings had revenue of $13.54M in the quarter ending December 31, 2025, a decrease of -57.92%.
Revenue (ttm)
$118.71M
Revenue Growth
-5.00%
P/S Ratio
0.73
Revenue / Employee
$2,046,776
Employees
58
Market Cap
86.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.71M | -6.25M | -5.00% |
| Dec 31, 2024 | 124.96M | -27.11M | -17.83% |
| Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
| Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
| Dec 31, 2021 | 111.01M | 4.74M | 4.46% |
| Dec 31, 2020 | 106.28M | -123.23M | -53.69% |
| Dec 31, 2019 | 229.50M | -82.27M | -26.39% |
| Dec 31, 2018 | 311.77M | -68.95M | -18.11% |
| Dec 31, 2017 | 380.72M | -75.17M | -16.49% |
| Dec 31, 2016 | 455.90M | 113.16M | 33.02% |
| Dec 31, 2015 | 342.74M | -47.63M | -12.20% |
| Dec 31, 2014 | 390.36M | 256.16M | 190.87% |
| Dec 31, 2013 | 134.21M | 43.39M | 47.78% |
| Dec 31, 2012 | 90.82M | -42.16M | -31.70% |
| Dec 31, 2011 | 132.97M | 52.21M | 64.64% |
| Dec 31, 2010 | 80.76M | 23.04M | 39.90% |
| Dec 31, 2009 | 57.73M | 22.89M | 65.69% |
| Dec 31, 2008 | 34.84M | -30.74M | -46.87% |
| Dec 31, 2007 | 65.58M | 56.03M | 586.65% |
| Dec 31, 2006 | 9.55M | 5.15M | 116.82% |
| Dec 31, 2005 | 4.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 112.82M |
| Journey Medical | 59.40M |
| Cumberland Pharmaceuticals | 44.52M |
| Alpha Teknova | 40.52M |
| BGM Group | 25.10M |
| Zhengye Biotechnology Holding | 21.46M |
| China SXT Pharmaceuticals | 1.54M |
ASRT News
- 5 days ago - Assertio Holdings, Inc. (ASRT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Assertio Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 18 days ago - Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 - Business Wire
- 2 months ago - Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements - Business Wire
- 2 months ago - Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial - Business Wire
- 3 months ago - Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split - Business Wire
- 4 months ago - Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Assertio Reports Third Quarter 2025 Financial Results - Business Wire